June 2026
Proprietary AI analyst is now available
Largest Diagnostics & Genomics Public Companies in China
Benchmark revenue and EBITDA valuation multiples for public comps like
Wantai BioPharm, Insight Lifetech, BGI Genomics, Vazyme Biotech and Novogene.
 | Beijing Wantai Biological Pharmacy Enterprise Co Ltd is engaged in research, development, production, and sales of in vitro diagnostic reagents, instruments, and vaccines. The company has two segments: Diagnostic and Vaccine. The Diagnostic segment develops and sells in vitro diagnostic reagents such as ELISA, colloidal gold, biochemical, and chemiluminescent kits, along with instruments including chemiluminescent analyzers, fluorescent analyzers, and nucleic acid purification systems. The Vaccine segment focuses on products like the hepatitis E vaccine, the bivalent HPV vaccine, and the nasal spray COVID-19 vaccine. It generates the majority of its revenue from the Diagnostic segment. | $5 | -44% | $6B | $6B | 21.3x | (301.6x) | ||
| Insight Lifetech Co Ltd is a medtech company. It is engaged in the research and development, production, and sale of medical devices used in the diagnosis and treatment of cardiovascular diseases. The company's core products are the TruePhysio pressure microcatheter and VivoCardio FFR system. | $6 | -- | $2B | $2B | 28.2x | 126.8x | ||
| BGI Genomics Co Ltd is a China-based company principally engaged in the provision of genomic class diagnosis and research services through the application of biotechnology. It offers its services in various research areas, such as agriculture and food science, cancer research, metagenomics, reproductive health, biomarker discovery, and drug discovery. The company mainly provides services for domestic and overseas academic institutions hospitals, medical institutions and others. | $5 | -29% | $2B | $2B | 3.2x | 40.1x | ||
| Nanjing Vazyme Biotech Co Ltd is a biotechnology company. It is committed to research and development both in technology and products focusing on functional proteins, such as enzymes, antigens, antibodies, and polymer organic materials. | $2 | -40% | $1B | $730M | 3.6x | 34.3x | ||
| Novogene Co Ltd is engaged in providing multi-level scientific research and technical services and solutions for life science basic research, medical and clinical application research, and independent development and innovation of genetic testing medical equipment. | $2 | -4% | $819M | $589M | 1.8x | 11.6x | ||
| New Horizon Health Ltd is engaged in early cancer screening and in-home testing in China. The company has an early detection and cancer screening-focused pipeline of five products and product candidates with an emphasis on colorectal cancer screening. The company focuses on cancer prevention and cure through screening and early detection. It generates maximum revenue from ColoClear and Pupu Tube products. | $4 | -- | $816M | $816M | - | - | ||
| 3D Medicines Inc is a commercial-stage biopharmaceutical company engaged in the research and development of oncology therapies for cancer patients, especially those who require long-term care. It develops differentiated immuno-oncology drugs, helping cancer patients live with prolonged survival time and quality of life. It generates all of its revenue from China. | $0 | -- | $94M | $52M | 1.0x | (2.1x) | ||
| Median | $4 | -35% | $1B | $816M | 3.4x | 22.9x |
Financial data powered by FactSet and Morningstar. Valuation multiples as of current fiscal year. For more data, start your free trial here.
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.